

SPHERIX INC
Form 8-K
March 13, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **March 12, 2012**

Spherix Incorporated

(Exact name of registrant as specified in its charter)

(State or other jurisdiction
of incorporation)

Delaware

(Commission
File Number)

0-5576

(I.R.S. Employer
Identification No.)

52-0849320

(Address of principal executive offices)

6430 Rockledge Drive, Suite 503, Bethesda, Maryland

(Zip Code)

20817

Registrant's telephone number, including area code **301-897-2540**

(Former name or former address, if changed since last report.)

Edgar Filing: SPHERIX INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure.

Dr. Robert Lodder, Company President, will present Molecular Factor Computing (MFC) of the Extent of Atherosclerosis in D-Tagatose Treatment, at the Pittcon Conference in Room 308D of the Orlando Convention Center, Orlando, FL, at 3:35 p.m. on March 12, 2012. The presentation is available on the Company's website at www.spherix.com, is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

Section 9 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

Exhibits

99.1 Spherix Incorporated Presentation, Molecular Factor Computing (MFC) of the Extent of Atherosclerosis in D-Tagatose Treatment, March 12, 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Spherix Incorporated
(Registrant)

By:

/s/ Robert L. Clayton
Robert L. Clayton
CFO

Date: March 12, 2012

Exhibit 99.1: Spherix Incorporated Presentation, Molecular Factor Computing (MFC) of the Extent of Atherosclerosis in D-Tagatose Treatment, March 12, 2012